

University of Groningen

Response to Rossato et al.

Ballering, Aranka Vivienne; Oertelt-Prigione, Sabine; Hartman, Tim C. Olde; Rosmalen, Judith G. M.

Published in:
Journal of womens health

DOI:
[10.1089/jwh.2022.0157](https://doi.org/10.1089/jwh.2022.0157)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2022

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Ballering, A. V., Oertelt-Prigione, S., Hartman, T. C. O., & Rosmalen, J. G. M. (2022). Response to Rossato et al. *Journal of womens health*, 31(6), 896-898. <https://doi.org/10.1089/jwh.2022.0157>

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

References

1. Ballering AV, Oertelt-Prigione S, Olde Hartman TC, et al. Sex and gender-related differences in COVID-19 diagnoses and SARS-CoV-2 testing practices during the first wave of the pandemic: The dutch lifelines COVID-19 cohort study. *J Women's Health (Larchmt)* 2021;30:1686–1692.
2. Pijls BG, Jolani S, Atherley A, et al. Demographic risk factors for COVID-19 infection, severity, ICU admission and death: A meta-analysis of 59 studies. *BMJ Open* 2021; 11:e044640.
3. Italian Institute of Health. Available at: <https://www.epicentro.iss.it/coronavirus/sars-cov-2-sorveglianza-dati> Accessed January 30, 2021.
4. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. *Cell* 2020; 181:271–280.e8.
5. Klein SL, Flanagan KL. Sex differences in immune responses. *Nat Rev Immunol* 2016;16:626–638.
6. Seeland U, Coluzzi F, Simmaco M, et al. Evidence for treatment with estradiol for women with SARS-CoV-2 infection. *BMC Med* 2020;18:369.

Address correspondence to:
 Marco Rossato, MD, PhD
 Clinica Medica 3
 Department of Medicine—DIMED
 University Hospital of Padova
 Via Giustiniani 2
 Padova 35128
 Italy

E-mail: marco.rossato@unipd.it

DOI: 10.1089/jwh.2022.0157

Open camera or QR reader and scan code to access this article and other resources online.



Response to Rossato et al.

Aranka Vivienne Ballering, MSc,^{1,*} Sabine Oertelt-Prigione, MD, PhD,² LCRI,*
 Tim C. Olde Hartman, MD, PhD,² and Judith G.M. Rosmalen, PhD¹

Dear Editor:

We thank Rossato et al. for their interest in our study and applaud their efforts to assess sex differences in coronavirus disease 2019 (COVID-19)-related mortality.¹ We agree with the authors that sex- and gender-related differences with regard to COVID-19 became apparent during the pandemic. For example, although our study shows no sex difference in COVID-19 diagnoses and testing in the general population, we do demonstrate that female health care workers have significantly lower odds of being tested and diagnosed with COVID-19 than male health care workers.² However, as the authors rightfully note, age is an important modifier in the association between sex and health outcomes.³

Therefore, we build further upon the analyses conducted by Rossato et al. by assessing sex differences in hospitalization rates due to COVID-19 in the Dutch Lifelines COVID-19 Cohort Study.^{4–6} As data collection proceeded, we included 20 consecutive measurements collected between March 2020 and March 2021, in contrast to our previous

study in which we included 13 consecutive measurements up to August 2020.² In total, 76,422 participants of the general population completed 774,826 questionnaires about their mental and physical health during the COVID-19 pandemic. During this time, the alpha variant (B.1.1.7) was predominant in the Netherlands and by the end of March 2021 a minority of participants were fully vaccinated (5.2%).

The majority of the COVID-19-positive participants in our study was female ($n=2,149$ female; 66.2%). However, previous studies show that male participants are more frequently hospitalized than female participants.^{7,8} Similarly, in our study, 41 women (1.9% of COVID-19-positive women) and 54 men (4.8% of COVID-19-positive men) were hospitalized due to COVID-19 ($\chi^2=22.0$; $Df=1$; $p<0.001$). The mean age of hospitalized women was 55.8 (standard deviation [SD]=12.0) years, compared with 59.0 (SD=10.7) years in men. This difference is not statistically significant ($t_{(92)}=1.06$; $p=0.29$). Bivariate logistic regression analysis shows that women have lower odds than men for hospitalization due to COVID-19 (odds ratio [OR]=0.38; 95% confidence interval [CI]=0.24–0.58).

¹Department of Psychiatry, University Medical Center Groningen, Interdisciplinary Center Psychopathology and Emotion Regulation (ICPE), University of Groningen, Groningen, The Netherlands.

²Department of Primary and Community Care, Radboud University medical Center, Nijmegen, The Netherlands.

*For members and affiliations, see Acknowledgment section.

Multiple logistic regression analysis, in which we adjusted for participants' age and the presence of chronic disease, shows that sex (OR = 0.44; 95% CI = 0.29–0.68), age (OR = 1.05; 95% CI = 1.03–1.08), and the presence of chronic disease (OR = 1.85; 95% CI = 1.14–3.02) are all significantly associated with hospitalization due to COVID-19. Sex-by-age and sex-by-chronic disease interaction terms were not statistically significant (OR = 1.01; 95% CI = 0.96–1.06 and OR = 0.77; 95% CI = 0.29–2.05, respectively). This indicates that the association between age and hospitalization, as well as the association between the presence of a chronic disease and hospitalization due to COVID-19 do not differ between women and men.

The lower odds of female hospitalization due to COVID-19 are most likely attributable to both sex- and gender-related factors. Women's innate and humoral immune responses, as well as their ability to balance inflammation and tissue damage, appear to be stronger than men's.^{7,9} These immunological sex differences may result in more effective clearing of infection in women and a potentially accelerated recovery after infection.¹⁰ In addition, higher age-adjusted rates of pre-existing somatic comorbidities are reported in male COVID-19 patients, including cardiovascular disease, which associate with a poor COVID-19 prognosis.^{11–13}

In addition to sex-specific factors, gender-related factors may also associate with the course of SARS-CoV-2 infection. For example, men are generally more likely to display poor health-related behaviors that worsen a COVID-19 prognosis, such as smoking and poor diet.^{14,15} The aforementioned sex-related factors may interact with gender-specific factors and thus synergistically influence the prognosis of COVID-19. Notably, sex- and gender-based differences regarding hospitalization due to COVID-19 may differ between cultures and location. In general, our findings regarding a female preponderance in COVID-19 diagnoses, but a poor male prognosis of COVID-19 are in line with those of Rossato et al. However, further research could focus on sex- and gender-based differences in physical consequences (*e.g.*, post-COVID-19 condition) and sociocultural consequences (*e.g.*, loss of productivity) due to COVID-19 and the pandemic in general.

Acknowledgments

The Lifelines Biobank initiative has been made possible by subsidy from the Dutch Ministry of Health, Welfare, and Sport; the Dutch Ministry of Economic Affairs; the University Medical Center Groningen (UMCG, The Netherlands); University of Groningen; and the Northern Provinces of the Netherlands. The authors wish to acknowledge the services of the Lifelines Cohort Study, the contributing research centers delivering data to Lifelines, and all the study participants. Lifelines Corona Research initiative: Marike Boezen (Department of Epidemiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands), Jochen O. Mierau (Faculty of Economics and Business, University of Groningen, Groningen, The Netherlands); Aletta Jacobs School of Public Health, Groningen, The Netherlands), Lude H. Franke (Department of Genetics, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands), Jackie Dekens (Department of Genetics, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands); Center of Development and Innovation, University Medical Center Groningen, University of Groningen,

Groningen, The Netherlands), Patrick Deelen (Department of Genetics, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands), Pauline Lanting (Department of Genetics, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands), Judith M. Vonk (Department of Epidemiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands), Ilja Nolte (Department of Epidemiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands), Anil P.S. Ori (Department of Genetics, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands); Department of Psychiatry, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands), Annique Claringbould (Department of Genetics, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands), Floranne Boulogne (Department of Genetics, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands), Marjolein X.L. Dijkema (Department of Genetics, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands), Henry H. Wiersma (Department of Genetics, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands), Robert Warmerdam (Department of Genetics, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands), and Soesma A. Jankipersadising (Department of Genetics, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands).

Author Disclosure Statement

No competing financial interests exist.

Funding Information

This study is supported by a grant from ZonMw (project no. 849200013).

References

1. Re: "Sex and Gender-Related Differences in COVID-19 Diagnoses and SARS-CoV-2 Testing Practices During the First Wave of the Pandemic: The Dutch Lifelines COVID-19 Cohort Study" by Ballering et al. *J Womens Health* 2022;31:895–896.
2. Ballering AV, Oertelt-Prigione S, LCRI, Olde Hartman TC, Rosmalen JGM. Sex and gender-related differences in COVID-19 diagnoses and SARS-CoV-2 testing practices during the first wave of the pandemic: The Dutch lifelines COVID-19 cohort study. *J Womens Health* 2021;30:1686–1692.
3. Green MS, Nitzan D, Schwartz N, Niv Y, Peer V. Sex differences in the case-fatality rates for COVID-19—A comparison of the age-related differences and consistency over seven countries. *PLoS One* 2021;16:e0250523.
4. McIntyre K, Lanting P, Deelen P, et al. Lifelines COVID-19 cohort: Investigating COVID-19 infection and its health and societal impacts in a Dutch population-based cohort. *BMJ Open* 2021;11:e044474.
5. Scholtens S, Smidt N, Swertz MA, et al. Cohort profile: LifeLines, a three-generation cohort study and biobank. *Int J Epidemiol* 2015;44:1172–1180.
6. Klijs B, Scholtens S, Mandemakers JJ, Snieder H, Stolk RP, Smidt N. Representativeness of the LifeLines cohort study. *PLoS One* 2015;10:e0137203.

7. Nachtigall I, Bonsignore M, Thürmann P, et al. Sex differences in clinical course and intensive care unit admission in a national cohort of hospitalized patients with COVID-19. *J Clin Med* 2021;10:4954.
8. Peckham H, de Groot NM, Raine C, et al. Male sex identified by global COVID-19 meta-analysis as a risk factor for death and ICU admission. *Nat Commun* 2020;11:6317.
9. Scully EP, Haverfield J, Ursin RL, Tannenbaum C, Klein SL. Considering how biological sex impacts immune responses and COVID-19 outcomes. *Nat Rev Immunol* 2020;20:442–447.
10. Bischof E, Oertelt-Prigione S, Morgan R, Klein SL, The Sex And Gender In Covid Clinical Trials Working Group Sgc, Gender And Covid Working Group. Towards precision medicine: Inclusion of sex and gender aspects in COVID-19 clinical studies-acting now before it is too late-A joint call for action. *Int J Environ Res Public Health* 2020;17:3715.
11. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. *Lancet* 2020;395:1054–1062.
12. Grasselli G, Zangrillo A, Zanella A, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy. *JAMA* 2020;323:1574–1581.
13. Petrilli CM, Jones SA, Yang J, et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York city: Prospective cohort study. *BMJ* 2020;369:m1966.
14. Haitao T, Vermunt JV, Abeykoon J, et al. COVID-19 and sex differences: Mechanisms and biomarkers. *Mayo Clin Proc* 2020;95:2189–2203.
15. Ahmed SB, Dumanski SM. Sex, gender and COVID-19: A call to action. *Can J Public Health* 2020;111:980–983.

Address correspondence to:
Aranka Viviënne Ballering
Department of Psychiatry
University Medical Center Groningen
Interdisciplinary Center Psychopathology
and Emotion Regulation (ICPE)
University of Groningen
P.O. Box 30.001, Internal Code CC72
Groningen 9700 RB
The Netherlands

E-mail: a.v.ballering@umcg.nl